Recent

% | $
Quotes you view appear here for quick access.

GenMark Diagnostics, Inc. Message Board

b_a_groover 4 posts  |  Last Activity: Jun 28, 2016 9:45 PM Member since: Mar 1, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • b_a_groover b_a_groover Jun 28, 2016 9:45 PM Flag

    You are just beside yourself because this may be the first board with so many people calling you on your BS every time you post it.

    Sentiment: Strong Sell

  • Reply to

    Why Michael McGarrity Needs To Be Concerned

    by jtrsteel80 Jun 28, 2016 7:04 PM
    b_a_groover b_a_groover Jun 28, 2016 7:55 PM Flag

    OH, so it wasn't you that was "a top 10 holder" now, it was "a group"?

    Here is an oldie but goodie that someone posted about you (when you were still using your norsemanwam alias here) after following you on other boards. It explains your ongoing mental issues to a tee.

    "Here's the Truth About Norse and the reason I'm going to invest in NSPH... Whether Norse is a complete Fraud or the worlds worst investor, draw your own conclusions. Stanerck is right about Norse, just check has past posts. His MO is always the same... He comes to a stock message board touting the stock and portraying himself as a great investor. He say the stock is a Tuck-in for a measly amount... He then turns on the CEO, the BOD, etc... and makes enemies with everyone on the message boards. He the says he's had it and announces he has sold all of his shares. The next thing that happens is that the stock he just claimed to have sold, takes off like a rocket.
    Sound familiar? I watched the same thing repeat itself with NVAX and MAKO.
    Thanks Norse... I'm going to buy a position in NSPH and hold on for the wild ride to the moon"

    Sentiment: Strong Sell

  • Reply to

    Why Michael McGarrity Needs To Be Concerned

    by jtrsteel80 Jun 28, 2016 7:04 PM
    b_a_groover b_a_groover Jun 28, 2016 7:28 PM Flag

    Why don't you tell the board how many shares you supposedly owned when you were supposedly "a top 10 holder in the company". That way everyone can go back and look at the filings over the last 3 years to determine the veracity of your rant.

    The top 10 holders have always been institutions.

    Sentiment: Strong Sell

  • That is the front page headline from EXAS' hometown paper this morning discussing the latest from USPSTF.

    "But it’s not clear if more doctors will order Cologuard now or if insurers will be required to cover the home-based stool test.

    “For myself personally, it really doesn’t change anything,” said Dr. David Feldstein, an internal medicine doctor at UW Health who heads up a committee that decides which screening tests to recommend at UW Health.

    “I like to make sure the evidence really supports what we’re doing,” Feldstein said. “That’s why I don’t recommend ... Cologuard.”

    "Dr. Michael Allan, a gastroenterologist at Dean Clinic, said Cologuard remains unproven compared to colonoscopy.

    Cologuard, recommended every three years, costs $509. A colonoscopy and its related costs are considerably more expensive, but it is recommended every 10 years and has more evidence, Allan said.

    “As (Cologuard is) priced right now, from a public health perspective, you’re still better off going in the direction of colonoscopy in terms of cost and colon cancer prevented,” he said.

    Dr. Gary Griglione, a gastroenterologist at UnityPoint Health-Meriter, said Cologuard detects only about half of polyps, precancerous lesions that colonoscopy is more likely to find.

    “We’re not screening for cancer; we’re screening for pre-cancer,” Griglione said. “What if (Cologuard) doesn’t turn positive until it’s a large enough polyp you can’t remove or actually has cancer in it?”

    "The UW Preventive Health Care Clinical Practice Guideline Steering Committee, which Feldstein leads, didn’t recommend Cologuard when it updated its colorectal cancer screening recommendations in early 2015.

    The committee will revisit the issue again early next year. Will Cologuard be recommended?

    “I’m not sure; it will be interesting,” Feldstein said. “The evidence really hasn’t changed.”

    Sentiment: Strong Sell

GNMK
11.70-0.08(-0.68%)Sep 23 4:00 PMEDT